ArriVent BioPharma Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
AVBP$13.49-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Series A · · Series B · · · · · · · · Additional · · · · · | |||||||||||||||||||||||||
| · · convertible preferred stock · · convertible preferred stock · · · Common stock · · paid-in · · Accumulated · · | |||||||||||||||||||||||||
| · Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · Total | |||||||||||||||||||||||||
| Balance January 1, 2023 | 150,000,000 | | $149,865 | 104,761,894 | | $109,706 | | 2,597,738 | | $— | | $3,403 | | $(88,512) | | $(85,109) | |||||||||
| Issuance of Series B convertible preferred stock at $1.05 per share, net of issuance costs of $57 | — | | — | 42,857,140 | | 44,943 | | — | | — | | — | | — | | — | |||||||||
| Exercise of stock options | — | | — | — | | — | | 11,417 | | — | | 26 | | — | | 26 | |||||||||
| Stock-based compensation expense | — | | — | — | | — | | — | | — | | 166 | | — | | 166 | |||||||||
| Net loss | — | | — | — | | — | | — | | — | | — | | (12,172) | | (12,172) | |||||||||
| Balance, March 31, 2023 | 150,000,000 | | $149,865 | 147,619,034 | | $154,649 | | 2,609,155 | | $— | | $3,595 | | $(100,684) | | $(97,089) | |||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| Balance January 1, 2024 | 150,000,000 | | $149,865 | 147,619,034 | | $154,625 | | | 2,745,480 | | $— | | $4,652 | | $(157,845) | | $(153,193) | ||||||||
| Issuance of common stock in initial public offering, net of issuance costs of $18,032 | — | | — | — | | — | | 11,180,555 | | 1 | | 183,216 | | — | | 183,217 | |||||||||
| Conversion of convertible preferred stock into common stock | | (150,000,000) | | | (149,865) | | (147,619,034) | | | (154,625) | | | 19,567,306 | | | 2 | | | 304,488 | | | — | | 304,490 | |
| Exercise of stock options | — | | — | — | | — | | 409 | | — | | 1 | | — | | 1 | |||||||||
| Stock-based compensation expense | — | | — | — | | — | | — | | — | | 625 | | — | | 625 | |||||||||
| Net loss | — | | — | — | | — | | — | | — | | — | | (17,417) | | (17,417) | |||||||||
| Balance, March 31, 2024 | — | | $— | — | | $— | | 33,493,750 | | $3 | | $492,982 | | $(175,262) | | $317,723 | |||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.